Target intelligence / Profile preview

Leukocyte Immunoglobulin-Like Receptor B1 (LILRB1)

Target: LILRB1
Molecular classification: Receptor, Glycoprotein, Immunoglobulin-like receptor

Overview

LILRB1 functions primarily as an inhibitory checkpoint receptor on diverse leukocytes by recognizing broad arrays of MHC class I ligands, dampening cellular activation through ITIM-mediated signaling, and represents both a fundamental regulator of self-tolerance/inflammation control and an emerging therapeutic target for cancer immunotherapy.

Other names: ILT2CD85jLIR-1

Mechanism of action

Inhibition of LILRB1 signaling, promotion of anti-tumor immunity

Biological functions

Immune regulationInhibition of cellular activationSuppression of cytotoxicityRegulation of inflammationProtection from cell death

Disease associations

CancerAutoimmune diseases

Beyond the preview

Go deeper on Leukocyte Immunoglobulin-Like Receptor B1 (LILRB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leukocyte Immunoglobulin-Like Receptor B1 (LILRB1).

Explore the full profile